CoChat

9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy

Open access
Han, Guangchun, Yang, Guoliang, Hao, Dapeng, Lu, Yang, Thein, Kyaw, Simpson, Benjamin S., Chen, Jianfeng, Sun, Ryan, Alhalabi, Omar, Wang, Ruiping, Dang, Minghao, Dai, Enyu, Zhang, Shaojun, Nie, Fengqi, Zhao, Shuangtao, Guo, Charles, Hamza, Ameer, Czerniak, Bogdan, Cheng, Chao, Siefker-Radtke, Arlene, Bhat, Krishna, Futreal, Andrew, Peng, Guang, Wargo, Jennifer, Peng, Weiyi, Kadara, Humam, Ajani, Jaffer, Swanton, Charles, Litchfield, Kevin, Ahnert, Jordi Rodon, Gao, Jianjun, Wang, Linghua · 2021 · Nature Communications
Cited by 225

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Immune checkpoint therapy (ICT) provides substantial clinical benefits to cancer patients, but a large proportion of cancers do not respond to ICT. To date, the genomic underpinnings of primary resistance to ICT remain elusive. Here, we performed immunogenomic analysis of data from TCGA and clinical trials of anti-PD-1/PD-L1 therapy, with a particular focus on homozygous deletion of 9p21.3 (9p21 loss), one of the most frequent genomic defects occurring in ~13% of all cancers. We demonstrate that 9p21 loss confers “cold” tumor-immune phenotypes, characterized by reduced abundance of tumor-infiltrating leukocytes (TILs), particularly, T/B/NK cells, altered spatial TILs patterns, diminished immune cell trafficking/activation, decreased rate of PD-L1 positivity, along with activation of immunosuppressive signaling. Notably, patients with 9p21 loss exhibited significantly lower response rates to ICT and worse outcomes, which were corroborated in eight ICT trials of >1,000 patients. Further, 9p21 loss synergizes with PD-L1/TMB for patient stratification. A “response score” was derived by incorporating 9p21 loss, PD-L1 expression and TMB levels in pre-treatment tumors, which outperforms PD-L1, TMB, and their combination in identifying patients with high likelihood of achieving sustained response from otherwise non-responders. Moreover, we describe potential druggable targets in 9p21-loss tumors, which could be exploited to design rational therapeutic interventions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-25894-9

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Cited by

See all 225

Metadata

Authors
Han, G., Yang, G., Hao, D., Lu, Y., Thein, K., Simpson, B. S., Chen, J., Sun, R., Alhalabi, O., Wang, R., Dang, M., Dai, E., Zhang, S., Nie, F., Zhao, S., Guo, C., Hamza, A., Czerniak, B., Cheng, C., Siefker-Radtke, A., Bhat, K., Futreal, A., Peng, G., Wargo, J., Peng, W., Kadara, H., Ajani, J., Swanton, C., Litchfield, K., Ahnert, J. R., Gao, J., & Wang, L.
Venue
Nature Communications
Published
2021-09-23
Volume
12
Issue
1
Pages
5606-5606
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3200875713
Cited by
225
References
30
FWCI
11.58
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. https://app.cochat.ai/papers/10.1038/s41467-021-25894-9
The paper
Han, G., Yang, G., Hao, D., Lu, Y., Thein, K., Simpson, B. S., Chen, J., Sun, R., Alhalabi, O., Wang, R., Dang, M., Dai, E., Zhang, S., Nie, F., Zhao, S., Guo, C., Hamza, A., Czerniak, B., Cheng, C., . . . Wang, L. (2021). 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature Communications. https://doi.org/10.1038/s41467-021-25894-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.